Interaksi Palonosetron

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Amfetamin, Peringatan dan perhatian)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (label Amfetamin dan dekstroamfetamin, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Beladona dan opium, Interaksi obat)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Buprenorfin, Interaksi obat)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Buprenorfin dan nalokson, Interaksi obat)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Butalbital, aspirin, kafein, dan kodein, Interaksi obat)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Butalbital, parasetamol, kafein, dan kodein, Interaksi obat)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Butorfanol, Perhatian)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (label Dekstroamfetamin, Peringatan)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Fentanil, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon, Interaksi obat)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan homatropin, Interaksi obat)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan ibuprofen, Perhatian)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan klorfeniramin, Interaksi obat)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan parasetamol, Perhatian)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidromorfon, Interaksi obat)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Kodein, Interaksi obat)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Levorfanol, Perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Lisdeksamfetamin, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Metadon, Peringatan dan perhatian)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (label Metaksalon, Interaksi obat)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Metamfetamin, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Morfin, Interaksi obat)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (label Oksikodon, Interaksi obat)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oksimorfon, Interaksi obat)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oliseridin, Interaksi obat)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Parasetamol dan kodein, Perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Pentazosin dan nalokson, Perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Prometazin dan kodein, Interaksi obat)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Remifentanil, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Mengombinasikan St. John's wort dengan antidepresan dan obat serotonergik lain meningkatkan risiko sindrom serotonin. (NCCIH, St. John's Wort)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (label Ziprasidon, Peringatan dan perhatian)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (label Palonosetron, Peringatan dan perhatian)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (label Nalbufin, Interaksi obat)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (label Palonosetron, Peringatan dan perhatian)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (label Fentermin, Peringatan dan perhatian)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (label Palonosetron, Peringatan dan perhatian)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (label Oksikodon dan parasetamol, Interaksi obat)

Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). (label Palonosetron, Peringatan dan perhatian)